TRICAPITAL

Sisaltech is a company that specializes in producing sustainable building insulation made from sisal, a natural fiber derived from the Agave plant. This material is durable, biodegradable, and has a low environmental impact during production. The company's primary business is to provide eco-friendly insulation solutions to the construction industry, offering a low-carbon alternative to traditional insulation materials. Sisaltech's products are designed to be easy to install, completely recyclable, and made with low-carbon materials, enabling clients to enhance safety and comfort while reducing their carbon footprint.

Kaly Group is a company focused on seaweed farming, dedicated to providing nature-based solutions to significant environmental challenges. It operates its own farms to cultivate seaweed, producing biostimulants and other products derived from this sustainable resource. The company serves various industries, delivering cultivated seaweed for use in food, animal feed, and fertilizers. Furthermore, Kaly Group integrates its operations vertically, allowing clients to utilize bio-based feedstock as alternatives in the manufacturing of plastics, cosmetics, pharmaceuticals, and textiles. With a commitment to exploration and innovation, Kaly Group combines its diverse interests to address pressing ecological issues through sustainable practices.

H2CHP is a developer of innovative free piston combined heat and power technology that focuses on generating electricity from waste heat. The company's solutions are designed to enhance the efficiency of fuel energy utilization by producing both electrical power and useful heat through co-generation systems. H2CHP specializes in zero-carbon fuels, allowing clients to generate energy in an environmentally friendly manner. This approach not only optimizes energy use but also supports sustainable practices across various applications.

HonuWorx is a technology company specializing in autonomous subsea robotics. It develops unmanned marine systems designed to deploy and control robots for offshore work, reducing reliance on large manned vessels. The company's edge-cloud architected software platform enables real-time data sharing, collaboration, supervision, and control of robotic systems beyond line-of-sight. This technology lowers operational expenses and environmental impact by minimizing travel requirements offshore, facilitating sustainable commercialization of ocean resources.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Heero Technologies is an energy service company focused on simplifying the energy retrofit process for homeowners. The company has developed a platform that provides personalized recommendations for improving home energy efficiency. By addressing challenges such as the disruptions caused by invasive retrofit measures and confusion surrounding financing options, Heero Technologies aims to enhance the user experience. This approach enables lenders and installers to differentiate their services and integrate renewable technologies within privately owned properties, ultimately contributing to reduced emissions and streamlined energy improvements.

Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to form natural antibodies against harmful targets. The company's innovative approach enhances the quality of treatment for chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. This not only helps to lower the overall cost of treatment for patients but also expands access to healthcare in markets with limited infrastructure. Through its advancements in biologic drug development, Glen Clova Scientific seeks to improve patient outcomes and provide effective therapeutic options.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

SellmyArtworks is to buy and sell pre-loved artwork in a simple, fast, and affordable way like no other pre-owned art seller.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative treatments for various medical conditions with significant unmet needs. Founded in 2010, Aurum is advancing its lead product, ABL101, which is designed for acute ischemic stroke management. This product employs a unique oxygen-carrying technology that operates independently of hemoglobin, potentially extending the therapeutic window for stroke treatment. Additionally, Aurum is advancing a proprietary image analysis software that enhances MRI assessments of stroke patients' brains. The company is also exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia. Aurum Biosciences is currently completing preclinical development and has plans to initiate clinical studies to evaluate the efficacy and safety of its treatments.

Beta Bugs is an insect genetics company specializing in the development and distribution of high-performance Black Soldier Fly breeds aimed at enhancing productivity in the insect protein sector. The company operates a breeding program called HiPer-Fly® and maintains a dedicated egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By focusing on biotechnology and breeding techniques, Beta Bugs aims to create a sustainable protein source that can effectively replace traditional feed ingredients such as fishmeal and soymeal in livestock, aquaculture, and pet feed. Headquartered at the Easter Bush Campus, a recognized center for animal genetics, Beta Bugs collaborates closely with the Roslin Institute, noted for its pioneering work in animal genetics.

Heero Technologies is an energy service company focused on simplifying the energy retrofit process for homeowners. The company has developed a platform that provides personalized recommendations for improving home energy efficiency. By addressing challenges such as the disruptions caused by invasive retrofit measures and confusion surrounding financing options, Heero Technologies aims to enhance the user experience. This approach enables lenders and installers to differentiate their services and integrate renewable technologies within privately owned properties, ultimately contributing to reduced emissions and streamlined energy improvements.

Heero Technologies is an energy service company focused on simplifying the energy retrofit process for homeowners. The company has developed a platform that provides personalized recommendations for improving home energy efficiency. By addressing challenges such as the disruptions caused by invasive retrofit measures and confusion surrounding financing options, Heero Technologies aims to enhance the user experience. This approach enables lenders and installers to differentiate their services and integrate renewable technologies within privately owned properties, ultimately contributing to reduced emissions and streamlined energy improvements.

Aveni is a video conferencing company that utilizes artificial intelligence and natural language processing to enhance client engagement for financial advisors. Its platform features a GPT-powered AI assistant that automates various tasks, including CRM functions and live risk monitoring. By providing tools for identifying risks and improving compliance, Aveni enables advisors to streamline their operations, increase efficiency, and better serve their clients while meeting regulatory requirements.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

Aveni is a video conferencing company that utilizes artificial intelligence and natural language processing to enhance client engagement for financial advisors. Its platform features a GPT-powered AI assistant that automates various tasks, including CRM functions and live risk monitoring. By providing tools for identifying risks and improving compliance, Aveni enables advisors to streamline their operations, increase efficiency, and better serve their clients while meeting regulatory requirements.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative treatments for various medical conditions with significant unmet needs. Founded in 2010, Aurum is advancing its lead product, ABL101, which is designed for acute ischemic stroke management. This product employs a unique oxygen-carrying technology that operates independently of hemoglobin, potentially extending the therapeutic window for stroke treatment. Additionally, Aurum is advancing a proprietary image analysis software that enhances MRI assessments of stroke patients' brains. The company is also exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia. Aurum Biosciences is currently completing preclinical development and has plans to initiate clinical studies to evaluate the efficacy and safety of its treatments.

Aveni is a video conferencing company that utilizes artificial intelligence and natural language processing to enhance client engagement for financial advisors. Its platform features a GPT-powered AI assistant that automates various tasks, including CRM functions and live risk monitoring. By providing tools for identifying risks and improving compliance, Aveni enables advisors to streamline their operations, increase efficiency, and better serve their clients while meeting regulatory requirements.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing innovative anti-infective medicines. Founded in 2009, the company specializes in a novel class of compounds known as DNA Minor Groove Binders (MGB), which exhibit antibacterial activity against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation specifically for the treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenge of antibiotic resistance by targeting bacteria in a way that minimizes the risk of inherent resistance, distinguishing its approach from traditional antibacterial therapies. The company’s experienced team combines expertise from both the pharmaceutical and biotechnology sectors, focusing on delivering effective solutions for healthcare providers and improving patient outcomes.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing innovative anti-infective medicines. Founded in 2009, the company specializes in a novel class of compounds known as DNA Minor Groove Binders (MGB), which exhibit antibacterial activity against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation specifically for the treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenge of antibiotic resistance by targeting bacteria in a way that minimizes the risk of inherent resistance, distinguishing its approach from traditional antibacterial therapies. The company’s experienced team combines expertise from both the pharmaceutical and biotechnology sectors, focusing on delivering effective solutions for healthcare providers and improving patient outcomes.

Blue Square Utilities Ltd is an independent smart meter installation company based in Newcastle upon Tyne, United Kingdom, serving small to medium-sized energy suppliers across the UK. Established in 2017, the company specializes in the installation and maintenance of both legacy and commercial metering services. Blue Square Utilities offers a comprehensive range of services including data management and control, scheduling, customer interaction, asset management, and accredited meter operator and meter asset manager services. The company’s team comprises fully qualified dual fuel smart meter installers, all registered with Energy & Utility Skills, ensuring a high level of expertise in the Smart Metering Rollout and providing an end-to-end solution for dual fuel smart meter installations.

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing innovative anti-infective medicines. Founded in 2009, the company specializes in a novel class of compounds known as DNA Minor Groove Binders (MGB), which exhibit antibacterial activity against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation specifically for the treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenge of antibiotic resistance by targeting bacteria in a way that minimizes the risk of inherent resistance, distinguishing its approach from traditional antibacterial therapies. The company’s experienced team combines expertise from both the pharmaceutical and biotechnology sectors, focusing on delivering effective solutions for healthcare providers and improving patient outcomes.

FINDRA is a Scottish brand specializing in high-performance outdoor and adventure clothing for women. The company focuses on designing stylish, versatile, and sustainable apparel made from Italian merino wool, which offers natural wicking properties. By providing high-quality clothing that balances performance and aesthetics, FINDRA encourages women to embrace outdoor activities and lead healthier, more active lifestyles. The brand's mission is to inspire women to pursue adventure without compromising on style or functionality, helping them to become better versions of themselves. Through its e-commerce platform, FINDRA promotes a commitment to sustainability while catering to the needs of adventurous women.

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative treatments for various medical conditions with significant unmet needs. Founded in 2010, Aurum is advancing its lead product, ABL101, which is designed for acute ischemic stroke management. This product employs a unique oxygen-carrying technology that operates independently of hemoglobin, potentially extending the therapeutic window for stroke treatment. Additionally, Aurum is advancing a proprietary image analysis software that enhances MRI assessments of stroke patients' brains. The company is also exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia. Aurum Biosciences is currently completing preclinical development and has plans to initiate clinical studies to evaluate the efficacy and safety of its treatments.

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, established in 2006. The company specializes in the development and commercialization of medical devices and pharmaceuticals centered around Lamellasomes, a synthetic substance that imitates the function of extra-alveolar lamellar bodies. Lamellar Biomedical's innovative products target various respiratory diseases, including cystic fibrosis, and conditions such as radiotherapy-induced xerostomia and dry eye disease. The company’s therapeutic platform leverages anti-infective properties to enhance antibiotic efficacy and protect lung tissues, particularly in complex cases like idiopathic pulmonary fibrosis. Additionally, it facilitates the intracellular delivery of genetic material for pulmonary disease treatment, aiming to provide transformative therapies for severe respiratory conditions. Lamellar Biomedical was previously known as Macrocom (964) Limited before adopting its current name in February 2007.

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing innovative anti-infective medicines. Founded in 2009, the company specializes in a novel class of compounds known as DNA Minor Groove Binders (MGB), which exhibit antibacterial activity against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation specifically for the treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenge of antibiotic resistance by targeting bacteria in a way that minimizes the risk of inherent resistance, distinguishing its approach from traditional antibacterial therapies. The company’s experienced team combines expertise from both the pharmaceutical and biotechnology sectors, focusing on delivering effective solutions for healthcare providers and improving patient outcomes.

Fios Genomics Ltd. is a bioinformatics company based in Edinburgh, United Kingdom, founded in 2008 as a spinout from the University of Edinburgh. The company specializes in providing a comprehensive range of data analysis services tailored for the pharmaceutical, biotech, and academic research sectors globally. Its offerings include microarray analysis, next-generation sequencing, and agricultural genomics, alongside proteomic and metabolomic services for biomarker identification and profiling. Fios Genomics also delivers bioinformatics consultancy, assisting clients with experimental design, data analysis, and technology selection. With a focus on pre-clinical and clinical development, drug repurposing, and stratified medicine applications, the company serves a diverse clientele, including major pharmaceutical and biotech firms, clinical centers, and academic institutions across the UK, US, EU, and Asia.

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

Fios Genomics Ltd. is a bioinformatics company based in Edinburgh, United Kingdom, founded in 2008 as a spinout from the University of Edinburgh. The company specializes in providing a comprehensive range of data analysis services tailored for the pharmaceutical, biotech, and academic research sectors globally. Its offerings include microarray analysis, next-generation sequencing, and agricultural genomics, alongside proteomic and metabolomic services for biomarker identification and profiling. Fios Genomics also delivers bioinformatics consultancy, assisting clients with experimental design, data analysis, and technology selection. With a focus on pre-clinical and clinical development, drug repurposing, and stratified medicine applications, the company serves a diverse clientele, including major pharmaceutical and biotech firms, clinical centers, and academic institutions across the UK, US, EU, and Asia.

The complexity and breadth of online media has reached a level where it is virtually impossible to manage your online marketing without clever software to help you. 4th aspect provides marketing professionals with tools that: measure, optimize and promote your content in virtually any form, across multiple content platforms and allows your marketing team to engage with advocates, influencers and of course customers. 4th aspect frees up your marketing resources and allows your team to create the content that your audience really cares about. Promote your brand on a global scale, while reducing costs and increasing control. Place your Brand ahead of your competitors and in front of your customers!

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

Smart Compliance Ltd, founded in 2010 by Scott Wallace and Billy Mitchell, specializes in innovative gas monitoring technology designed to enhance safety in residential and commercial properties. The company has developed a detector that not only identifies the presence of hazardous gases, such as carbon monoxide and natural gas, but also communicates this information externally. This feature allows landlords and real estate agents to monitor appliance safety without needing physical access to the property. The device alerts individuals inside the building to potential dangers and provides warnings to those outside, ensuring compliance with health and safety regulations. Through its technology, Smart Compliance aims to improve safety standards and facilitate better risk management in the real estate sector.

Inquisitive Systems Ltd. is a data protection software company based in Edinburgh, United Kingdom, established in 2008 as a spin-out from Edinburgh Napier University. Founded by Dr. Jamie Graves and Professor Bill Buchanan, the company aims to become a leader in information security software. Inquisitive Systems developed its core technology, foxDNATM, during Dr. Graves' postgraduate research focused on enhancing digital forensic investigations. The software is designed to protect intellectual property from security breaches, analyze relevant data, provide alerts, and monitor forensic user activity. After securing a grant from Scottish Enterprise, the company began commercial operations in 2010, focusing on delivering innovative solutions to address growing cybersecurity challenges.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, established in 2006. The company specializes in the development and commercialization of medical devices and pharmaceuticals centered around Lamellasomes, a synthetic substance that imitates the function of extra-alveolar lamellar bodies. Lamellar Biomedical's innovative products target various respiratory diseases, including cystic fibrosis, and conditions such as radiotherapy-induced xerostomia and dry eye disease. The company’s therapeutic platform leverages anti-infective properties to enhance antibiotic efficacy and protect lung tissues, particularly in complex cases like idiopathic pulmonary fibrosis. Additionally, it facilitates the intracellular delivery of genetic material for pulmonary disease treatment, aiming to provide transformative therapies for severe respiratory conditions. Lamellar Biomedical was previously known as Macrocom (964) Limited before adopting its current name in February 2007.

pureLiFi Ltd. is a light communications technology company based in Edinburgh, United Kingdom, that specializes in developing Li-Fi, a visible light communications technology. By utilizing the visible light spectrum instead of traditional radio frequencies, pureLiFi enables wireless data communication. The company offers various products, including Li-1st, which allows customers to develop and test VLC applications; Li-Flame, a secure wireless network solution; and the Li-Fire Platform, which supports wireless communications through light. Its technology is applicable in diverse fields such as smart lighting, healthcare, aviation, and location-based services, addressing issues like RF spectrum relief and enhancing mobile connectivity. Originally founded as pureVLC Ltd. in 2012, the company rebranded in 2013 to reflect its focus on Li-Fi solutions.

Blackford Analysis Ltd. is a software company based in Edinburgh, United Kingdom, that specializes in enhancing the comparison of medical images to improve productivity in healthcare settings. Founded in 2010 as a spin-out from the University of Edinburgh, the company develops a range of tools designed for seamless integration into existing imaging systems. Key products include the Blackford Workflow Server, which facilitates the deployment of pre-processing capabilities within hospital IT frameworks, and the Blackford Smart Localizer, which allows for quick comparisons of multiple imaging studies with a single click. Blackford's software leverages advanced algorithms and multi-core processing technologies to deliver significant time savings—typically between 10% and 20%—for clinicians. The company collaborates with various imaging system providers, such as Philips and Intelerad Medical Systems, as well as industries beyond diagnostic imaging, to enhance diagnostic confidence and patient outcomes. Blackford Analysis continues to expand its presence, with sales offices in the United States and the United Kingdom.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

Fios Genomics Ltd. is a bioinformatics company based in Edinburgh, United Kingdom, founded in 2008 as a spinout from the University of Edinburgh. The company specializes in providing a comprehensive range of data analysis services tailored for the pharmaceutical, biotech, and academic research sectors globally. Its offerings include microarray analysis, next-generation sequencing, and agricultural genomics, alongside proteomic and metabolomic services for biomarker identification and profiling. Fios Genomics also delivers bioinformatics consultancy, assisting clients with experimental design, data analysis, and technology selection. With a focus on pre-clinical and clinical development, drug repurposing, and stratified medicine applications, the company serves a diverse clientele, including major pharmaceutical and biotech firms, clinical centers, and academic institutions across the UK, US, EU, and Asia.

DesignLED, established in 2003, specializes in designing and manufacturing innovative LED lighting solutions. The company is renowned for its LED light tiles, which combine optical, electrical, beam angle, and mechanical features. DesignLED's product portfolio includes shelf luminaires, signage and backlighting products, and solutions for various lighting applications. Serving diverse sectors such as architecture, retail, automotive, and custom products, the company operates under brands like Edinburgh, Ness, and Clyde. With a passion for LED technology and a commitment to driving change in the lighting industry, DesignLED aims to provide low energy, highly differentiated, and cost-effective solutions, supported by strategic partnerships.

Sphinx Medical Ltd. is a company located in Bellshill, Scotland, United Kingdom. It develops the artificial sphincter Flow-Secure, which has been sold in Europe for 9 years. It is an innovative device that enables the treatment of severe Male Urinary Incontinence.

IRT Surveys Limited, established in 2002 and headquartered in Dundee, UK, specializes in non-destructive building testing using infrared thermal imaging technology. The company offers a range of services including thermal imaging surveys, energy audits, air leakage detection, electronic leak detection, and maintenance planning. They also provide energy performance certificates to help clients identify defects and inefficiencies in their properties, enabling informed decision-making for future planning.

Actual Analytics Limited specializes in behavior analysis solutions for scientific research, leveraging advanced video analysis technology to monitor animal behavior automatically. The company’s flagship products include ActualTrack, which tracks the movements of lab animals such as rodents, drosophila, and zebrafish, and Actual Home Cage Analysis (ActualHCA), which facilitates non-invasive data collection and automated analysis of behaviors in group-housed rodents. This technology is particularly valuable in drug development for diseases affecting the Central Nervous System, allowing researchers to streamline the monitoring process, reduce errors, and cut costs associated with manual observation. Established in 2009 and headquartered in Edinburgh, United Kingdom, Actual Analytics distributes its products in various markets, including the United States, Spain, Taiwan, China, and Germany.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing innovative anti-infective medicines. Founded in 2009, the company specializes in a novel class of compounds known as DNA Minor Groove Binders (MGB), which exhibit antibacterial activity against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation specifically for the treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenge of antibiotic resistance by targeting bacteria in a way that minimizes the risk of inherent resistance, distinguishing its approach from traditional antibacterial therapies. The company’s experienced team combines expertise from both the pharmaceutical and biotechnology sectors, focusing on delivering effective solutions for healthcare providers and improving patient outcomes.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

IRT Surveys Limited, established in 2002 and headquartered in Dundee, UK, specializes in non-destructive building testing using infrared thermal imaging technology. The company offers a range of services including thermal imaging surveys, energy audits, air leakage detection, electronic leak detection, and maintenance planning. They also provide energy performance certificates to help clients identify defects and inefficiencies in their properties, enabling informed decision-making for future planning.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, founded in 2005. The company specializes in developing a patented Kromex chemistry scaffold aimed at generating New Chemical Entities (NCE) for regenerative medicine applications and mitochondrial-related diseases. The Kromex scaffold, informed by extensive research in free radical biology and redox chemistry, encompasses a library of over 100 million compounds with potential therapeutic effects on oxidative stress-associated diseases and mitochondrial dysfunction. Antoxis focuses on two primary drug families: Proxison, which enhances the efficacy of regenerative medicine therapies and holds promise for treating neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator designed to improve outcomes in drug-resistant cancer by demonstrating synergy with existing cancer treatments.

Exterity is a provider of enterprise-class building IPTV solutions, established in 2001. The company offers products that enable organizations to distribute broadcast-quality digital TV and video over IP networks, allowing for centralized management and control. With a presence in 29 countries and a customer base exceeding 1,000, including major global corporations, Exterity's solutions cater to a wide range of applications. The services also encompass digital signage, leveraging video to communicate, educate, and entertain effectively. By facilitating the distribution of large volumes of content to numerous endpoints, Exterity ensures high system performance and reliability, making it a key player in the digital media landscape.

Biopta Ltd. is a contract research organization based in Glasgow, United Kingdom, specializing in human tissue-based services for the pharmaceutical industry. Founded in 2002, the company utilizes ethically donated residual human tissue from surgeries to predict drug activity prior to clinical trials. Biopta provides a range of services, including laboratory and comparative pharmacology, clinical biopsies, and both in-vitro and ex-vivo techniques. Their expertise spans several therapeutic areas, offering services related to cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary functions. In addition, Biopta maintains a catalogue of human functional tissue assays, which includes various standard assays. The organization operates laboratories in Glasgow and Maryland and functions as a subsidiary of ReproCELL, Inc. since December 2015.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

Founded in 2003 by Graeme Bryce and Dave Reynolds, Factonomy licenses its technology framework to companies to help them reduce the time and cost it takes to develop applications. Factonomy's agile software environment enables the rapid development of web-enabled business applications using declarative XML only. Unlike other development platforms, the Factonomy Framework allows developers to work independently on functionality, content and style, providing a coherent end-to-end environment so they can deliver solutions which are flexible and cost effective.

Turnbull & Scott (Engineers) Ltd, established in 1933, is a British engineering company specializing in the generation, transfer, and recovery of heat. The company manufactures a range of products, including heat exchangers, heating and cooling coils, economizers, and waste heat recovery systems, designed to meet the heating requirements of various industrial and commercial applications. With over 80 years of combined experience across sectors such as nuclear, food processing, oil and gas, and pharmaceuticals, Turnbull & Scott has built a strong reputation for delivering robust and reliable heating solutions tailored for harsh environments or challenging locations. The company prides itself on its British manufacturing heritage and commitment to quality, supported by a highly skilled workforce. As an Investor in People and a partner of the University of Strathclyde, Turnbull & Scott is dedicated to advancing high-performance heating technologies to address contemporary industrial challenges.

PowerPhotonic Limited is a manufacturer of precision micro-optics primarily for laser projection systems, optical telecommunications, and industrial materials processing. Founded in 2004 and headquartered in Dalgety Bay, United Kingdom, the company specializes in designing and fabricating various optical components, including high-powered diode laser optics, microlens array optics, beam shapers, and refractive diffusers. It also offers custom solutions such as beam correction phase plates and application-specific micro-optic arrays. PowerPhotonic serves a diverse client base through a network of distributors both in the UK and internationally, with operational reach extending into North America and Southeast Asia. The company is recognized for its advanced micro-optical fabrication technology and its commitment to providing comprehensive optics solutions to meet specific industrial needs.

Touch Bionics Limited, established in 2003 and headquartered in Livingston, United Kingdom, specializes in developing and distributing advanced upper-limb prosthetics for individuals with upper limb deficiencies. The company's product portfolio includes the i-LIMB Hand, a multi-articulating bionic hand; Prosthetic Digits, self-contained fingers for partial hand patients; and ProDigits, a bionic finger solution for those missing fingers. Touch Bionics serves customers in various regions worldwide, including North America, Europe, Asia, Australia, and South Africa. As of April 2016, the company operates as a subsidiary of Össur hf.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, founded in 2005. The company specializes in developing a patented Kromex chemistry scaffold aimed at generating New Chemical Entities (NCE) for regenerative medicine applications and mitochondrial-related diseases. The Kromex scaffold, informed by extensive research in free radical biology and redox chemistry, encompasses a library of over 100 million compounds with potential therapeutic effects on oxidative stress-associated diseases and mitochondrial dysfunction. Antoxis focuses on two primary drug families: Proxison, which enhances the efficacy of regenerative medicine therapies and holds promise for treating neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator designed to improve outcomes in drug-resistant cancer by demonstrating synergy with existing cancer treatments.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

Gas Sensing Solutions Ltd. is a manufacturer of carbon dioxide sensors, headquartered in Glasgow, United Kingdom. The company specializes in innovative CO2 sensor technology that caters to various applications, including building control, horticulture, education, process control, and analytical instrumentation. Its product lineup includes the COZIR Ambient sensors, designed for HVAC and indoor air quality management; the COZIR Wide Range sensors, suitable for applications in diving, industrial safety, and automotive sectors; and the SprintIR, a high-speed CO2 sensor intended for metabolic assessment. In addition to its sensor products, Gas Sensing Solutions offers tailored hardware and software development services to meet specific client needs. Established in 2005, the company has positioned itself as a key player in the gas sensing industry.